Currently Viewing:
American Society of Hematology
Currently Reading
Dr Derek Raghavan Explains How Use of Guidelines Can Address Issues of Cost and Variation
May 26, 2018
Dr Shannon Maude: The Novelty of CAR T Treatments Requires Patient Education
May 01, 2018
Dr Derek Raghavan Provides Best Practices for Implementing Guidelines
April 26, 2018
Dr Thomas LeBlanc on the Importance of Shared Decision Making in Cancer Care
April 18, 2018
Dr Stephen Schuster: Unique CAR T Toxicities Require Provider Education
April 17, 2018
Dr Derek Raghavan Addresses the Concept of "Cookbook Medicine"
April 09, 2018
Dr Nina Shah Outlines New Treatments Being Studied for Multiple Myeloma
April 07, 2018
Dr Thomas LeBlanc: How to Increase Palliative Care Among Patients With Blood Cancer
April 02, 2018
Dr Thomas LeBlanc on Improving End-of-Life Outcomes for Patients With Blood Cancer
March 21, 2018
Dr Thomas LeBlanc: Patients With Blood Cancer and Palliative Care
March 10, 2018
Julie Wolfson: Supporting AYAs Before and After Treatment
January 14, 2018
Dr Julie Wolfson on What Clinicians Need to Understand About Adolescents/Young Adults With ALL
December 30, 2017
Dr Nina Shah on the Impact of New Treatments for Multiple Myeloma
December 29, 2017
Dr Stephen Schuster on Institution Commitments to Deliver CAR T Therapies
December 28, 2017
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25, 2017
Diagnosing Congenital Neutropenia
December 23, 2017
Dr Derek Raghavan: Ensuring Guidelines Are Implemented and Followed
December 22, 2017
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 18, 2017
Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs
December 18, 2017

Dr Nina Shah on the Benefits of Outpatient HSCT When Possible

Providing outpatient hematopoietic stem cell transplant (HSCT) when patients are eligible is a good way to reduce costs, without impacting outcomes, explained Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.


Providing outpatient hematopoietic stem cell transplant (HSCT) when patients are eligible is a good way to reduce costs, without impacting outcomes, explained Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.

Transcript

Would it be more cost efficient to conduct outpatient hematopoietic stem cell transplant if outcomes are comparable and proven safe compared with inpatient transplant?

We just published a paper on this, this year from a large group of patients. And what we know is for patients who are eligible, and this is often a decision that’s between the physician and the patient, patients who are eligible for an outpatient transplant, they do great. They do just as well. And there is less cost to the entire medical system.

I think that that if we’re going to use that approach, we have to get insurance companies to get on board to help patients pay for things like, for example, hotel rooms near the transplant center, or helping a caregiver with their off time from work. And that will actually be more cost efficient than having the patient in the hospital for 16, 18, 20 days, and patients actually feel more free, that they can do things a little more freely without being tied to a hospital bed. So I’d really like to see us work together with the payers.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!